New drug cocktail shows promise in tough pancreatic cancer fight
NCT ID NCT03264404
First seen Jan 29, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This study tested a combination of two drugs, pembrolizumab and azacitidine, in people with advanced pancreatic cancer that had stopped responding to initial treatment. The goal was to see if this combo could slow or stop the cancer from growing. 36 participants received the treatment at a single center, and researchers measured how long they lived without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.